Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four pharmaceutical agents—amoxicillin, clavulanic acid, fluconazole, and levofloxacin. - **Amoxicillin** is a penicillin-class antibiotic that inhibits bacterial cell wall synthesis. - **Clavulanic acid** is a beta-lactamase inhibitor that protects amoxicillin from degradation by beta-lactamase enzymes produced by resistant bacteria[1][2][3][4][5][6]. - **Fluconazole** is an antifungal agent (not described in the provided search results but widely known) that inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol synthesis and thus fungal cell membrane formation. - **Levofloxacin** is a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, essential for DNA replication and repair[7][10]. This combination would provide broad antibacterial coverage (including Gram-positive and Gram-negative bacteria) as well as antifungal activity. There are no known approved or marketed products containing all four agents together; such combinations may be used in specific clinical scenarios under medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clavulanic acid + fluconazole + levofloxacin.